KERYX TO PRESENT PHASE II RESULTS AT CONFERENCE

Keryx Biopharmaceuticals has announced that final data from the company's Phase II study of KRX-101 (oral sulodexide gelcap) for diabetic nephropathy will be presented at the upcoming American Society of Nephrology's Renal Week in Philadelphia, Pa.

KRX-101, the company's lead compound for the treatment of diabetic nephropathy, is currently in a global pivotal Phase III and Phase IV clinical program.